艾昂尼斯制药
IONS
42.94
-1.18
-2.67%
艾昂尼斯制药
US · IONS
#1749 按市值排名
上市于 1970
42.94
-1.18
-2.67%
实时 - 追踪5344个代码 - 心跳于513秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了3家。
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 109.71% -0.32pp
- 机构数量
- 617 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund87.92%
Hedge Fund11.75%
Public Company5.25%
VC/PE Fund1.80%
Government Pension Fund1.29%
Private Company1.24%
Individual/Insider0.78%
Insurance Company0.21%
主要股东 截至 2026-06-30
FMR
14.82% · 24.63M 股
Capital Research
13.73% · 22.82M 股
BlackRock
6.44% · 10.70M 股
Vanguard Capital Management, LLC
4.98% · 8.27M 股
Vanguard Portfolio Management, LLC
4.73% · 7.86M 股
Wellington Management Group
4.60% · 7.65M 股
T. Rowe Price Group, Inc.
4.30% · 7.14M 股
Two Sigma Investments, LP
3.76% · 6.25M 股
State Street Global Advisors
2.61% · 4.33M 股
Geode Capital Management, LLC
2.16% · 3.58M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 26次买入 · 24次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Brett Monia | Chief Executive Officer | 0.15% |
| Spencer Berthelsen | Independent Director | 0.10% |
| Brian Birchler | Executive Vice President of Corporate & Development Operations | 0.06% |
| Elizabeth Hougen | Chief Financial Officer | 0.05% |
| Michael Hayden | Independent Director | 0.05% |
| Eugene Schneider | Executive VP & Chief Clinical Development Officer | 0.05% |
| C. Bennett | Chief Scientific Officer | 0.05% |
| Richard Geary | Chief Development Officer | 0.04% |
| Patrick O'Neil | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | 0.04% |
| Joseph Baroldi | Executive VP & Chief Business Officer | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-30 | C. Bennett | Chief Scientific Officer | Other Acquisition | +110 | $51.31 |
| 2026-08-30 | Brett Monia | Chief Executive Officer | Other Acquisition | +98 | $51.31 |
| 2026-08-30 | Patrick O'Neil | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | Other Acquisition | +63 | $51.31 |
| 2026-08-30 | Brian Birchler | Executive Vice President of Corporate & Development Operations | Other Acquisition | +58 | $51.31 |
| 2026-07-30 | Michael Hayden | Independent Director | Open Market Acquisition | +20,000 | $51.60–53.38 |
| 2026-07-14 | Joan Herman | Independent Director | Derivative Exercise and Retained | +5,220 | -- |
| 2026-07-14 | Spencer Berthelsen | Independent Director | Derivative Exercise and Retained | +5,220 | -- |
| 2026-07-14 | Ludwig Hantson | Director | Other Derivative Acquisition | +3,399 | -- |
| 2026-07-14 | Peter Reikes | Former Independent Director | Other Derivative Acquisition | +3,399 | -- |
| 2026-07-06 | C. Bennett | Chief Scientific Officer | Other Acquisition | +15,000 | -- |
| 2026-07-06 | C. Bennett | Chief Scientific Officer | Automatic Disposition | -20,536 | $83.58–85.46 |
| 2026-07-06 | C. Bennett | Chief Scientific Officer | Other Derivative Disposition | -15,000 | -- |
| 2026-07-06 | Allene Diaz | Independent Director | Derivative Exercise and Sale | -10,111 | $47.11–85.42 |
| 2026-07-06 | Holly Kordasiewicz | Senior Vice President of Neurology | Automatic Disposition | -362 | $84.30 |
| 2026-06-30 | Joan Herman | Independent Director | Other Derivative Acquisition | +2,301 | -- |
| 2026-06-30 | Joan Herman | Independent Director | Other Derivative Acquisition | +5,369 | $79.19 |
| 2026-06-30 | Joseph Klein | Independent Director | Derivative Exercise and Sale | -11,518 | $39.94–79.45 |
| 2026-06-30 | Joseph Klein | Independent Director | Other Derivative Acquisition | +2,301 | -- |
| 2026-06-30 | Joseph Klein | Independent Director | Other Derivative Acquisition | +5,369 | $79.19 |
| 2026-06-30 | Michael Hayden | Independent Director | Other Derivative Acquisition | +2,301 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
艾昂尼斯制药 讨论区 0 条评论